Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gleave

Showing results (431-440 of 941) with videos related to

Pageof 95
Sort By:
Plant Science : an International Journal of Experimental Plant Biology|August 13, 2025
Silencing microRNA172 delays fruit ripening in apple (Malus domestica) through an AP2-ERF transcriptional regulation mechanismBin Xia, Jinquan Feng, Yarong Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 16, 2012
Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancerVirginie Baylot, Maria Katsogiannou, Claudia Andrieu, et al.
Molecular and Cellular Biology|February 16, 2006
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinaseMatthew J Martin, Nataliya Melnyk, Michelle Pollard, et al.
Breast Cancer Research : BCR|December 15, 2007
Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicityMaximino Redondo, Teresa Téllez, Maria J Roldan, et al.
Der Urologe. Ausg. A|August 2, 2008
[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer]B A Hadaschik, K Zhang, A I So, et al.
Molecular Cancer Therapeutics|October 1, 2014
The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancerNaokazu Ibuki, Mazyar Ghaffari, Hadas Reuveni, et al.
The Prostate|February 19, 2010
Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancerMarie-Claude Battista, Marie-Odile Guimond, Claude Roberge, et al.
Journal of the National Cancer Institute|September 8, 2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerKim N Chi, Elizabeth Eisenhauer, Ladan Fazli, et al.
BJU International|May 15, 2004
Protein kinase C-alpha in prostate cancerM Lahn, K Sundell, M Gleave, et al.
BJU International|November 15, 2008
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapyClement Mugabe, Boris A Hadaschik, Rajesh K Kainthan, et al.
Pageof 95

Showing results (431-440 of 941) with videos related to

Sort By:
Pageof 95
Plant Science : an International Journal of Experimental Plant Biology|August 13, 2025
Silencing microRNA172 delays fruit ripening in apple (Malus domestica) through an AP2-ERF transcriptional regulation mechanismBin Xia, Jinquan Feng, Yarong Wang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 16, 2012
Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancerVirginie Baylot, Maria Katsogiannou, Claudia Andrieu, et al.
Molecular and Cellular Biology|February 16, 2006
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinaseMatthew J Martin, Nataliya Melnyk, Michelle Pollard, et al.
Breast Cancer Research : BCR|December 15, 2007
Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicityMaximino Redondo, Teresa Téllez, Maria J Roldan, et al.
Der Urologe. Ausg. A|August 2, 2008
[Oncolytic vesicular stomatitis viruses as intravesical agents against non-muscle-invasive bladder cancer]B A Hadaschik, K Zhang, A I So, et al.
Molecular Cancer Therapeutics|October 1, 2014
The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancerNaokazu Ibuki, Mazyar Ghaffari, Hadas Reuveni, et al.
The Prostate|February 19, 2010
Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancerMarie-Claude Battista, Marie-Odile Guimond, Claude Roberge, et al.
Journal of the National Cancer Institute|September 8, 2005
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerKim N Chi, Elizabeth Eisenhauer, Ladan Fazli, et al.
BJU International|May 15, 2004
Protein kinase C-alpha in prostate cancerM Lahn, K Sundell, M Gleave, et al.
BJU International|November 15, 2008
Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapyClement Mugabe, Boris A Hadaschik, Rajesh K Kainthan, et al.
Pageof 95